Iplex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recognition of severe igf 1 deficiency, limitations of growth hormone therapy, development of recombinant igf therapies, specialist driven treatment protocols, orphan drug incentives.

The growth in the forecast period can be attributed to improved diagnosis of growth disorders, expansion of pediatric endocrinology services, rising awareness among caregivers, continued orphan drug support, advancements in recombinant protein production. Major trends in the forecast period include treatment of rare pediatric growth disorders, use of recombinant growth factor therapies, focus on reducing hypoglycemia risk, specialized endocrinology care expansion, long term pediatric hormonal management.

The increasing prevalence of growth hormone deficiencies (GHD) is expected to drive the expansion of the Iplex (mecasermin rinfabate) market. GHD refers to a condition where the pituitary gland fails to produce enough growth hormone, leading to impaired physical growth and developmental issues in both children and adults. The rise in the incidence of GHD can be attributed to factors such as improved diagnostic techniques, greater awareness of endocrine disorders, and the increasing prevalence of conditions like genetic mutations, tumors, or traumatic brain injuries, all of which can impair growth hormone production. Iplex (mecasermin rinfabate) helps treat growth hormone deficiencies by providing insulin-like growth factor-1 (IGF-1) combined with IGF-binding protein-3, which promotes growth and enhances metabolic activity. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based non-professional organization, reported that the UK cystic fibrosis registry had exceeded 11,318 individuals in 2023, with adults representing a substantial share of the patient base - 63.7% were aged over 16, and 16.7% were over 40. This underscores a growing and aging cystic fibrosis population. As such, the increasing incidence of GHD is expected to fuel the growth of the Iplex market.

The increasing pediatric population is expected to drive the growth of the Iplex market. The pediatric population includes individuals from birth to 18 years, who require specialized care for their growth, development, and age-specific medical needs. The expansion of the pediatric population is primarily due to higher birth rates, improvements in healthcare that reduce child mortality, and greater awareness of childhood health needs, all contributing to a growing demand for pediatric services and treatments. Iplex plays a key role in this expanding pediatric population by providing targeted IGF-1 therapy for children with growth hormone deficiencies, promoting proper growth and development, especially when traditional treatments are ineffective. For example, in July 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that the number of births in the United States increased by 1% from 2023 to 2024, reaching 3,628,934 births. As a result, this growing pediatric population is a key driver for the expansion of the Iplex market.

The rising investment in healthcare research and development is also expected to propel the growth of the Iplex market in the coming years. Healthcare research and development encompass scientific studies aimed at discovering new treatments, enhancing existing therapies, and innovating technologies to improve patient care and public health outcomes. The increase in healthcare R&D investment is driven by the need for innovative treatments, technological advancements, and the growing burden of chronic and rare diseases. These investments ensure better healthcare outcomes and address unmet medical needs. The funding in healthcare R&D directly supports the manufacturing and development of Iplex by improving innovation, treatment efficacy, and production capabilities. For instance, in January 2025, the National Institutes of Health (NIH), a U.S.-based government agency, reported that the NIH invests the majority of its nearly $48 billion budget into medical research aimed at enhancing life and reducing illness and disability. Therefore, increasing investment in healthcare research and development is driving the growth of the Iplex market.

Major companies operating in the iplex market are Insmed Incorporated.

North America was the largest region in the Iplex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iplex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the iplex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the iplex market by raising costs for recombinant protein production materials and specialized manufacturing equipment. Pediatric hospitals and specialty endocrinology clinics in import dependent regions are most affected. These cost pressures may limit accessibility for rare disease patients. However, tariffs are also encouraging localized biologics manufacturing and regional partnerships. This supports long term availability of orphan growth therapies.

The iplex market research report is one of a series of new reports that provides iplex market statistics, including iplex industry global market size, regional shares, competitors with a iplex market share, detailed iplex market segments, market trends and opportunities, and any further data you may need to thrive in the iplex industry. This iplex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Iplex (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF binding protein-3 (IGFBP-3). It is used to treat severe primary IGF-1 deficiency, which helps promote growth in children. By stabilizing IGF-1, Iplex enhances cellular growth, metabolism, and development, while reducing the risk of hypoglycemia associated with free IGF-1.

The main patient demographic for Iplex is pediatric patients, which includes individuals aged 0 to 18 years who require specialized medical care for growth and development. Iplex is used in these patients to treat growth hormone deficiencies, offering targeted IGF-1 therapy to support proper growth and development, particularly when traditional treatments are ineffective. It is distributed through multiple channels, including hospitals, retail pharmacies, specialty pharmacies, and online pharmacies, and is applied in the treatment of growth hormone deficiency and other related disorders.

The iplex market consists of sales of mecasermin rinfabate (rDNA origin) injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.